This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Digital pharmacies seem to be springing up everywhere. It’s convenient for most but having a CVS pharmacy on almost every street corner allows patients to use drive-throughs to pick up their medications. CVS is competing against several start-up pharmacies that have no physical locations.
Compounding pharmacies, which involve the preparation and selling of prescribed medicines are gaining massive popularity across the healthcare sector owing to the rising awareness regarding the benefits of compounded medications.
For 2025, the three largest pharmacy benefit managers (PBMs)Caremark (CVS Health), Express Scripts (Cigna), and Optum Rx (United Health Group)have again each excluded hundreds of drugs from their standard formularies. In fact, nearly all marketed Humira biosimilars are excluded from the larger PBMs 2025 formularies.
The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a limited grace period before taking any enforcement actions.
Pharmacies and Pharmacy Benefit Managers is now available for purchase and immediate download. Pharmacies and PBMs, Examining $683 Billion Market Review pricing/license options and download the full 2025 report Order before March 31, 2025 to receive special discounted pricing! Pharmacies and Pharmacy Benefit Managers.
Despite what you may have heard, pharmacy participation in the 340B Drug Pricing Program continues to thrive. Drug Channels Institute’s latest analysis reveals that an astonishing 32,000 pharmacy locations —more than half of the entire U.S. Is this really what Congress intended when the 340B program was established in 1992?
Drug Channels Institute’s (DCI’s) latest analysis finds that participants in the specialty pharmacymarket continue to get more diverse—although revenues remain highly concentrated. Read on for DCI’s latest overview of the 2023 marketplace and revenues of the biggest market participants, along with key specialty pharmacy trends.
Increasing diagnosis of chronic diseases is expected to lead to fast growth in retail pharmacies. The rising incidence of long-standing diseases such as hypertension, diabetes, cardiovascular diseases, and cancer requires prolonged medication and, thus, drives the growth and need for retail pharmacies in the market.
Sam Crowther, founder and CEO of cybersecurity company Kasada, tells us about a recent discovery his company made that revealed tens of thousands of accounts with prescription drug attachments in major online pharmacies had been compromised. Detection of fraudulent activity. “The [implications of these stolen accounts] are twofold.
Pharmacies and Pharmacy Benefit Managers. The total share of the largest 15 companies decreased slightly compared with their 2020 share, due primarily to below-market growth rates at retail and long-term care pharmacies. Read on as we cue up our latest update on the booming pharmacy and PBM marketplace.
Pfizer said it expected the drug, marketed under the name Zavzpret, to be available in pharmacies in July 2023. ”The FDA approval of Zavzpret marks a significant breakthrough for people with […]
The retail pharmacy shakeout affected 2021 pharmacist employment. We found that retail pharmacies and drugstores employed fewer pharmacists, while hospitals and outpatient centers continued to add positions. Time for an update to the Drug Channels Institute (DCI) annual analysis of pharmacist salaries and employment.
On February 13, it was revealed that Novo Nordisk’s Wegovy (semaglutide) would be available in high-street pharmacies in the UK this spring. Wegovy is a glucagon-like peptide 1 receptor agonist (GLP-1RA) therapy that offers efficacy and treatment duration advantages within the obesity market.
Pharmacies and Pharmacy Benefit Managers. Pharmacies and Pharmacy Benefit Managers is a definitive, nonpartisan resource that includes the most current information about pharmacy dispensing channels, third-party payers, pharmacy benefit managers (PBMs), patients’ financial contributions, government regulations, and much more.
In 2022, the PBM market remained highly consolidated—although there were some intriguing share shifts among the largest players. Below, you’ll find Drug Channels Institute's latest estimates of pharmacy benefit manager (PBM) market share based on equivalent prescription claims. to 1:30 p.m.
Pharmacies and Pharmacy Benefit Managers. The largest 15 pharmacies accounted for more than 75% of total dispensing revenues from retail, mail, long-term care, and specialty pharmacies. How will GoodRx and Mark Cuban Cost Plus Drug Company affect the pharmacy industry? to 1:30 p.m.
Pharmacies and Pharmacy Benefit Managers , available for purchase and immediate download. Prescription Market (press release) We’re offering special discounted pricing if you order before March 28, 2022. Prescription Market (press release) We’re offering special discounted pricing if you order before March 28, 2022.
Pharmacies and Pharmacy Benefit Managers. Pharmacies and Pharmacy Benefit Managers is a definitive, nonpartisan resource that includes the most current information about pharmacy dispensing channels, third-party payers, pharmacy benefit managers (PBMs), patients’ financial contributions, government regulations, and much more.
Pharmacies and Pharmacy Benefit Managers , available for purchase and immediate download. Prescription Market (press release) We’re offering special discounted pricing if you order before April 3, 2023. Prescription Market (press release) We’re offering special discounted pricing if you order before April 3, 2023.
Pharmacies and Pharmacy Benefit Managers. prescription dispensing revenues reached $621 billion in 2023, driven by accelerating GLP-1 prescriptions and an expanding post-pandemic market. How will the most consequential change in federal drug pricing policy affect the largest pharmacies and PBMs? to 1:30 p.m.
Three is still the magic number for pharmacy benefit managers (PBMs). Read on for Drug Channels Institute’s (DCI’s) latest market share figures, along with a preview of the industry changes that will shift these shares over the next few years.
In the video excerpt below, I walk through a brief history of 340B contract pharmacies. I conclude with a “follow the dollar” example of 340B prescription economics with contract pharmacies. If this clip whets your appetite for more, register to watch a replay of the full 90-minute video webinar from June. All rights reserved.
has skyrocketed in recent years driven primarily by an increase in chronic condition diagnosis and the number of new medications on the market. The problem is, many specialty pharmacies don’t currently have the right tools to support their patients. The use of specialty drugs in the U.S. Determining prior authorisation and eligibility.
As many of you know, hospitals and health systems have emerged as significant participants in the specialty pharmacy industry. A new American Society of Hospital Pharmacists (ASHP) survey provides fresh insights into these specialty pharmacies. Below, I review key findings on the economics and operations of these specialty pharmacies.
Our exclusive analysis of these numbers finds that for 2022, an astounding 99% of seniors are enrolled in the wonderland of PDPs with preferred pharmacy networks. Below, we use the new enrollment data to examine the major pharmacy chains’ position within the 27 major Part D plans that have preferred networks. DOWN THE DATA RABBIT HOLE.
Amazon Pharmacy launched a pair of TV spots last month to showcase the ease of its drug delivery service for consumers. One of the ads is titled “Mom,” in which a man is seen waiting in a long line at a pharmacy to pick up his mom’s medication because she didn’t listen to him when he told her to send her prescription to Amazon Pharmacy.
Despite this, specialty generics are expected to be the domain of a handful of companies with the necessary manufacturing capabilities and legal backing needed for entering the market. As more competitors enter the market, the price of a treatment goes down, explains Stanford University professor of medicine Dr. Kevin Schulman.
billion acquisition of One Medical, a primary care provider with 188 offices in 25 markets nationwide but are they making a strategic move or a mistake? I prefer a face-to-face appointment where I can effectively diagnose a patient based on what I see” 5ive: Will Amazon use my data to market to me? 4our: Can HCPs trust patients?
This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Discount Cards, Cost-Plus Pharmacies, and PBMs: Trends, Controversies, and Outlook. The rise of discount card pricing within pharmacy benefit plans is a positive development. Links below. d/b/a Drug Channels Institute.
When you head to the pharmacy to pick up medicine, you likely aren’t thinking about all the steps it had to take to get into your hands — but did you know that on average, it takes about ten years for a new medication to make it to market ?
Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for a new video webinar: Discount Cards, Cost-Plus Pharmacies, and PBMs: Trends, Controversies, and Outlook This event will be broadcast live on Friday, March 31, 2023, from 12:00 p.m. Pharmacies and Pharmacy Benefit Managers.
In Medicare Part D in 2024: The Seven Largest Companies' Preferred Pharmacy Networks and the Coming Collapse of the PDP Market , I documented how those networks now dominate stand-alone Medicare Part D prescription drug plans (PDPs) and have become a major presence in Medicare Advantage prescription drug (MA-PD) plans.
In a previous article , I highlighted the largest pharmacy chains that will participate in the 2024 Medicare Part D prescription drug plans (PDP). Plans from Aetna, Humana, WellCare, and UnitedHealthcare will not have any independent pharmacies participating via PSAOs as preferred pharmacies. Look out below!
The highly-consolidated PBM market notched another year of increased concentration. Consider Drug Channels Institute's latest estimates of pharmacy benefit manager (PBM) market share, shown in the chart below. Significant business relationships among the largest companies continue to shift market share.
CVS Health and Walgreens have become the first two US pharmacy chains to agree a settlement worth nearly $10 billion to answer allegations they played a role in the opioid epidemic that has claimed tens of thousands of lives. ” The post Pharmacy chains agree $10bn settlement in opioid litigation appeared first on.
As the market for patient-paid prescriptions has expanded, disputes about the appropriate split of these spreads will pressure pharmacy-PBM relationships and drive change in the discount card business model. As I explain below, the unnamed chain appears to be Kroger— the sixth-largest U.S.
The rise of discount card pricing within pharmacy benefit plans is a positive development. Patients get access to market prices that can be lower than their PBM’s contracted rate. Links below. All out-of-pocket spending with a discount card counts toward a patient's deductibles, and all prescription activity gets captured.
Looks like pharmacy and PBM profiteering within the 340B Drug Pricing Program will never go out of style. Drug Channels Institute’s (DCI) latest analysis reveals that more than 33,000 pharmacy locations —more than half of the entire U.S. Read on for my latest effort to pierce these little webs of 340B opacity.
The highly-consolidated PBM market notched another year of increased concentration. Consider Drug Channels Institute's latest estimates of pharmacy benefit manager (PBM) market share, shown in the chart below. Significant business relationships among the largest companies continue to shift market share.
Informa Connect's Hub and Specialty Pharmacy Models West. September 14-15, 2022 Sheraton San Diego Hotel & Marina | San Diego, CA www.informaconnect.com/hub-specialty-pharmacy-west. Delivered as a Hybrid Event. Drug Channels readers will save 10% off the current registration rate when they use code 22DC10 *.
In this issue: Green Monster : The 340B market hits new highs in 2021 Not-Free Agents : Big 340B profits for CVS, Walgreens, Express Scripts, et al Batter Up : Fixing the insulin market Pinch Hitters : Walgreens bets on robots Plus, Dr. Glaucomflecken helps UnitedHealthcare celebrate Doctors’ Day! Hope to see you there!
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content